Media stories about Invuity (NASDAQ:IVTY) have trended somewhat positive on Monday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Invuity earned a news impact score of 0.15 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 47.6222002899132 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Invuity from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Northland Securities reissued a “buy” rating and set a $13.00 price target on shares of Invuity in a research report on Tuesday, September 26th. Piper Jaffray Companies reissued a “buy” rating and set a $12.00 price target on shares of Invuity in a research report on Friday, November 10th. Finally, ValuEngine raised shares of Invuity from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $11.67.

Invuity (IVTY) opened at $6.70 on Monday. The company has a current ratio of 2.90, a quick ratio of 2.47 and a debt-to-equity ratio of 5.39. The firm has a market cap of $118.26 and a PE ratio of -2.73. Invuity has a 1 year low of $5.70 and a 1 year high of $9.70.

Invuity (NASDAQ:IVTY) last announced its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04. The firm had revenue of $9.60 million for the quarter, compared to analysts’ expectations of $9.87 million. Invuity had a negative net margin of 111.43% and a negative return on equity of 212.38%. analysts expect that Invuity will post -2.41 earnings per share for the current year.

WARNING: This news story was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at

Invuity Company Profile

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Insider Buying and Selling by Quarter for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with Analyst Ratings Network's FREE daily email newsletter.